Show Results For
- All HBS Web
(610)
- People (4)
- News (110)
- Research (426)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
Show Results For
- All HBS Web
(610)
- People (4)
- News (110)
- Research (426)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
- 15 May 2007
- First Look
First Look: May 15, 2007
- June 1998
- Supplement
MBA Integrative Exercise: General Management, April 1998
V. Kasturi Rangan
Kash Rangan is the Malcolm P. McNair Professor of Marketing at the Harvard Business School. Formerly the chairman of the Marketing Department (1998-2002), he is now the co-chairman of the school's Social Enterprise Initiative. He has taught in a wide variety of MBA... View Details
- April 2009
- Case
Merck: Managing Vioxx (A)
Ranjay Gulati
Ranjay Gulati is the Paul R. Lawrence MBA Class of 1942 Professor of Business Administration and the former Unit Head of the Organizational Behavior Unit at Harvard Business School. His pathbreaking research, which focuses on unlocking organizational and unleashing... View Details
- 21 Apr 2009
- First Look
First Look: April 21, 2009
- June 2023 (Revised June 2023)
- Supplement
Roche: ESG and Access to Healthcare
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
- December 2019
- Case
The Business of Pain: Johnson & Johnson and the Promise of Opioids
Rosabeth M. Kanter
Rosabeth Moss Kanter holds the Ernest L. Arbuckle Professorship at Harvard Business School, specializing in strategy, innovation, and leadership for change. Her strategic and practical insights guide leaders worldwide through teaching, writing, and direct... View Details
- April 2023
- Case
Elliott Management: Capital Allocation in Biopharma
Rohit Deshpande
Rohit Deshpandé is a Baker Foundation Professor and Sebastian S. Kresge Professor of Marketing, Emeritus at Harvard Business School, where he has been teaching in the Advanced Management Program,... View Details
- November 2006 (Revised May 2025)
- Case
Eli Lilly: Developing Cymbalta
- December 2008 (Revised October 2013)
- Case
Amylin Pharmaceuticals: Diabetes and Beyond (A)
William A. Sahlman
William Sahlman is a Baker Foundation Professor of Business Administration at Harvard Business School.
Mr. Sahlman received an A.B. degree in Economics from Princeton University (1972), an M.B.A. from Harvard University (1975), and a Ph.D. in Business... View Details
- September 2010 (Revised July 2013)
- Case
Alnylam Pharmaceuticals: Building Value from the IP Estate
- October 2014 (Revised July 2016)
- Supplement
Gilead: Hepatitis C Access Strategy (B)
- June 2020
- Case
Breakthroughs at Blueprint Medicines
- 16 Aug 2011
- Working Paper Summaries
Managing Political Risk in Global Business: Beiersdorf 1914-1990
Stefan H. Thomke
Stefan Thomke (sthomke@hbs.edu), an authority on the management of innovation, is the William Barclay Harding Professor of Business Administration at Harvard Business School. He has worked with firms on product, process, and... View Details